{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(6)"],"submitter":["Dempke WCM"],"pubmed_abstract":["Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies have provided compelling evidence that c-MET is involved in the regulation of the immune response by up-regulating inhibitory molecules (e.g., PD-L1) and down-regulating of immune stimulators (e.g., CD137, CD252, CD70, etc.). In addition, c-MET was found to be implicated in the regulation of the inflamed tumour microenvironment (TME) and thereby contributing to an increased immune escape of tumour cells from T cell killing. Moreover, it is a major resistance mechanism following treatment of epiderm"],"journal":["Translational lung cancer research"],"pagination":["2667-2682"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8264346"],"repository":["biostudies-literature"],"pubmed_title":["Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative review."],"pmcid":["PMC8264346"],"pubmed_authors":["Fenchel K","Dempke WCM"],"additional_accession":[]},"is_claimable":false,"name":"Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative review.","description":"Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies have provided compelling evidence that c-MET is involved in the regulation of the immune response by up-regulating inhibitory molecules (e.g., PD-L1) and down-regulating of immune stimulators (e.g., CD137, CD252, CD70, etc.). In addition, c-MET was found to be implicated in the regulation of the inflamed tumour microenvironment (TME) and thereby contributing to an increased immune escape of tumour cells from T cell killing. Moreover, it is a major resistance mechanism following treatment of epiderm","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T09:37:43.005Z","creation":"2025-04-04T09:37:43.005Z"},"accession":"S-EPMC8264346","cross_references":{"pubmed":["34295669"],"doi":["10.21037/tlcr-21-124"]}}